<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3447">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062033</url>
  </required_header>
  <id_info>
    <org_study_id>EVA-19350</org_study_id>
    <nct_id>NCT03062033</nct_id>
  </id_info>
  <brief_title>Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents</brief_title>
  <acronym>RE-Kinect</acronym>
  <official_title>Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Evidera</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in
      outpatient psychiatry practices in the United States (US), as well as to describe the
      associated disease burden in a cohort of patients with one or more psychiatric disorders and
      a cumulative lifetime exposure to antipsychotic medication of three months or more.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Customized clinician‐reported outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Clinician evaluation of patient burden due to tardive dyskinesia symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EuroQOL 5 Dimensions EQ-5D-5L)</measure>
    <time_frame>12 months</time_frame>
    <description>General, single index measure for describing and valuing health-related quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Customized caregiver‐reported outcomes:</measure>
    <time_frame>12 months</time_frame>
    <description>Caregiver evaluation of perceived burden of symptoms on patients as well as the impact on the caregiver</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of functional impairment and disability</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Tardive Dyskinesia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must be 18 years or older with a cumulative lifetime exposure to antipsychotic
        medication of three months or more.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a cumulative lifetime exposure to antipsychotic medication of three
             months or more

          -  Patient has a clinician confirmed diagnosis of one or more psychiatric disorder(s),
             as defined in the DSM‐5

          -  Patient has a usual care clinic visit scheduled during the study recruitment window
             (i.e. a pre‐defined 2‐week period)

          -  Patient is able to read and understand English

          -  Patient is willing and able to comply with the study requirements

        Exclusion Criteria:

          -  Patient is unable to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris O'Brien, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evidera RE-Kinect Registry Team</last_name>
    <phone>1-800-242-2196</phone>
    <email>rekinect@evidera.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>February 3, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
